7月8日 -
** 制药商伊顿制药ETON.O股价盘前上涨3.5%至14.90美元
** 该公司称美国食品及药物管理局已接受其候选药物ET-600的潜在批准申请
** ETON称，如果获得批准，ET-600有望成为市场上治疗中枢性尿崩症的唯一口服液体药物
** 中枢性糖尿病是指人体不能产生足够的血管加压素，这种激素通过向肾脏发出节水信号来调节水平衡。
** 美国食品和药物管理局将于 2026 年 2 月 26 日或之前就 ET-600 做出决定
** 截至上一交易日收盘，股价已累计上涨 8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.